| dc.description.abstract | Tuberculosis (TB) ) is highly infectious and still remains a global health problem
although improvements in diagnostic, drug susceptibility tests [1,2] and supported
national programs. The emergence of strains resistant to the major anti-TB drugs
speed up the need for rapid methods for the detection of MDR-TB to treat disease
effectively and, at the same time, prevent the spread of resistant strains. In order
to increase the ability to detect RIF and INH resistance, a new version of the
GenoType MTBDR assay, the GenoType MTBDRplus assay, that covers more
mutations has recently been developed. The GenoType MTBDRplus assay targets
the mutations included in the previous test and includes a broader selection of
probes for the wild-type rpoB gene and the hot spot region (of the rproB
mutation1=MUT1; mutation2A=MUT2A; mutation 2B=MUT2B; mutation 3=MUT3,
and a base-pair change in codon 315 of the katG gene with MUT1; MUT2, followed
by mutations in position -15 of the inhA gene promoter region: inhA MUT1; MUT2,
MUT3A; MUT3B. The purpose of this project is to apply GenoType MTBDRplus test
(Hain Lifescience GmbH, Nehren, Germany) as a rapid diagnostic tool to predict
INH and/or RIF resistance directly applied from smear-positive clinical specimens.
Key words: Tuberculosis, GenoType MTBDRplus, Multidrug-resistance, Rifampicin
(RIF), Isoniazid (INH). | en_US |
